Whh. Sheu et al., Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia, METABOLISM, 50(3), 2001, pp. 355-359
Recent studies have shown that statins are effective in reducing fasting lo
w-density lipoprotein-cholesterol (LDL-C) and triglyceride levels. However,
it remains unknown if treatment with statins also lowers daily postprandia
l triglyceride concentrations, which may promote atherogenesis in type 2 di
abetes subjects. Forty-one subjects with type 2 diabetes and combined hyper
lipidemia who had stable glycemic control were randomly assigned to take si
mvastatin 20 mg (n = 27) or a placebo (n = 14) once daily for 12 weeks. The
medication dosage was doubled after 4 weeks if a subject's LDL-C was not l
ess than 130 mg/dL. Among these participants, 24 subjects (15 on simvastati
n and 9 on placebo) agreed to take a meal tolerance test with isocaloric mi
xed meals (carbohydrate, 52%; fat, 33%, and protein, 15% of the daily calor
ic intake) and daytime hourly blood sampling from 8 AM to 4 PM. Simvastatin
treatment reduced the fasting total cholesterol level from 237 +/- 5 to 17
8 +/- 6 mg/dL (-25%), the LDL cholesterol level from 150 +/- 6 to 87 +/- 5
mg/dL (-40%), and raised high-density lipoprotein-cholesterol (HDL-C) level
from 36 +/- 2 to 40 +/- 2 mg/dL (+11%) (all P <.001). Fasting and daily am
bient triglyceride concentrations from 8 AM to 4 PM decreased significantly
in response to simvastatin administration (P <.001), but not to the placeb
o (P =.305). Simvastatin treatment not only decreased total cholesterol and
LDL-C levels and increased HDL-C levels effectively, it also decreased fas
ting, as well as daily postprandial triglyceride concentrations, but had no
effect on glycemic control in type 2 diabetes subjects with combined hyper
lipidemia. Copyright (C) 2001 by W.B. Saunders Company.